Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Thoracic 2Other solid neoplasm 2Dermatologic 2Breast 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Solid Tumor 1Locally Advanced or Metastatic Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × efineptakin alfa × Other solid neoplasm × Clear all
NCT03733587 2020-05-14

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Genexine, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumor

NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Genexine, Inc.

Phase 1 Completed
35 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡